Dr. Ian Gilham Appointed Chairman of the Board for Horizon Discovery
News Jan 14, 2014
Dr. Gilham was Chief Executive Officer of Axis-Shield plc, the in vitro diagnostics company acquired by Alere in November 2011 for £235 million. Before its sale to Alere, Axis-Shield’s revenues rose above £100 million and the Company issued a maiden dividend. Prior to joining Axis-Shield, Dr. Gilham held international general management, marketing, business development and R&D positions with GSK, Abbott Laboratories, Celltech and Amersham, gaining wide expertise in the fields of pharmaceuticals and clinical diagnostics.
Dr. Gilham is also currently non-executive Chairman of Multiplicom, focused on the development and commercialization of innovative molecular genetic tests; and Biosurfit SA, focused on development and commercialization of point-of-care diagnostic products.
Dr. Darrin Disley, CEO of Horizon, commenting on the announcement, said: “We are delighted that Ian has decided to accept the position of Chairman of the Board on a permanent basis. As interim Chairman he has made an invaluable contribution to the growth and success of the Company and we look forward to benefitting from his guidance as Horizon continues to develop as a world-leading translational genomics organization.”
Dr. Gilham added: “I believe Horizon Discovery is one of the World’s most innovative and promising life science organizations and I am very excited to continue to support the Company as Chairman. I am looking forward to working with the team during the next stages of the Company’s growth and development.”
A human pluripotent stem cell line has been engineered which contains two ‘suicide genes’ that induce cell death in all but the desired insulin-producing cells. This double fail-safe approach opens the door to creating safe cell-replacement therapies for people living with type 1 diabetes.READ MORE
Birch pollen allergic rhinitis is the most common chronic disorder in the Northern part of the globe, and it attributes to significant morbidity and economic burden. According to a new study, pollen allergen immunotherapy has favorable effects on the molecular events and microbiome profile in the nasal membrane.READ MORE
In a study of mice and human brain tumors researchers searched for new treatments by exploring the reasons why some patients with gliomas live remarkably longer than others. The results suggested that certain patients’ tumor cells are less aggressive and much better at repairing DNA than others but are difficult to kill with radiation.READ MORE